Puma Biotechnology(US:PBYI)2025-05-09 01:14Financial Performance - Net NERLYNX revenue in Q1'25 was $43.1 million[6], a ~7% increase compared to Q1'24[9] when it was $40.3 million[7], but a ~21% decrease compared to Q4'24[9] when it was $54.4 million[10] - Inventory change in Q1'25 was -$4.7 million[8, 11] - 2,338 ex-factory bottles of NERLYNX were sold in Q1'25[12], a ~3% decrease compared to Q1'24[15] when 2,410 bottles were sold[13], and a ~21% decrease compared to Q4'24[15] when 2,964 bottles were sold[16] - Inventory change in bottles was -251 in Q1'25[14, 17] NERLYNX Dosage - Approximately 72% of patients in Q1'25 started NERLYNX at a reduced dose (fewer than 6 pills per day)[18, 19, 20] Rest of World Partnerships - Puma has established partnerships for NERLYNX commercialization in various regions including Australia/SE Asia, Israel, Canada, Latin America, Europe, Greater China, Middle East, North and West Africa, South Africa, Turkey, South Korea, and Russia/CIS[23] - These partnerships have resulted in regulatory approvals and commercial launches in multiple countries across these regions, with ongoing expansion[23]